Translate Bio (TBIO) Prices 12.507M Share Common Offering at $22/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
SunTrust Starts Translate Bio (TBIO) at Buy
June 26, 2020 5:30 AM EDTSunTrust analyst Joon Lee initiates coverage on Translate Bio (NASDAQ: TBIO) with a Buy rating and a price target of $40.00.
For an analyst ratings summary and ratings history on Translate Bio click here. For more ratings news on Translate Bio click here.
Shares of Translate Bio closed at $24.67 yesterday.
... MoreTranslate Bio (TBIO) PT Raised to $35 at Citi
June 26, 2020 5:23 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Translate Bio (NASDAQ: TBIO) to $35.00 (from $17.00) while maintaining a Buy rating.... More
Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources
June 25, 2020 10:23 AM EDTBy Matthias Blamont
PARIS (Reuters) - Sanofi is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs.
Management will meet staff representatives on Friday and Monday next week to outline a restructuring plan, five sources familiar with the matter told Reuters. They declined to be identified as the plan is still confidential.
The reorganisation could involve several European countries and possibly others outside the region, as... More
Pre-Open Stock Movers 06/25: (EKSO) (GNC) (ALLY) Higher; (MGTA) (KBH) (XERS) Lower (more...)
June 25, 2020 9:26 AM EDTPre-Open Stock Movers
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) 79% HIGHER; received 501(k) clearance from the U.S. Food and Drug Administration (FDA) to market its EksoNRTM robotic exoskeleton for use with patients with acquired brain injury (ABI). EksoNR is the first exoskeleton device to receive FDA clearance for rehabilitation use with ABI, significantly expanding the devices indication to a broader group of patients.
GNC Holdings, Inc. (NYSE: GNC) 36.3% HIGHER; bankrupt stock sees upside
Magenta Therapeutics, Inc.... More
After-Hours Movers 06/24: (ALLY) (BDN) (RPAI) Higher; (XERS) (QURE) (NK) Lower (more...)
June 24, 2020 5:46 PM EDTAfter-Hours Movers
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) 14.9% LOWER; announced that it has commenced concurrent underwritten public offerings of $20,000,000 in shares of its common stock (the Shares) and $60,000,000 aggregate principal amount of convertible senior notes due 2025 (the Notes).
uniQure N.V. (NASDAQ: QURE) 12.8% LOWER; announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQures investigational gene therapy for patients with hemophilia B. Etranacogene... More
Translate Bio (TBIO) Announces $125 Million Proposed Public Offering of Common Stock
June 24, 2020 4:19 PM EDTTranslate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has commenced an underwritten public offering of $125.0 million of its common stock. In addition, Shire Human Genetic Therapies, Inc. (Shire), a... More
